Michael P Dube sold $23k of NTLA
VP, Chief Accounting Officer at Intellia Therapeutics, Inc.. 1,864 shares at an average of $12.43, traded Oct 2, 2026, filed Oct 6, 2026.
Score components
- +15RoleOfficer
- 0Trade size$23k at market
- 0Share of holdings soldSold 2.8% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-415541, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | SOpen-market sale Common Stock | -1,864 | $12.43 | $23k | 65,022 | 6 d ago |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $33k 1,871 shares | -3% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | William J Chase director | $1.0M 100,000 shares | +288% | |
| 32Weak | NTLAsell Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $105k 7,462 shares | -7% | |
| 30Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $10k 1,022 shares | -1% | |
| 30Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $25k 2,503 shares | -4% | |
| 20Weak | Intellia Therapeutics, Inc. | Jesse Goodman director | $29k 3,094 shares | -11% | |
| 0Weak | Intellia Therapeutics, Inc. | Muna Bhanji director | $2,253 265 shares | -1% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $23k 2,572 shares | -2% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $6,104 679 shares | -1% | |
| 0Weak | Intellia Therapeutics, Inc. | Muna Bhanji director | $2,642 265 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.